The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Autolus Therapeutics announces participation in upcoming conferences

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November.

Truist Securities BioPharma Symposium
Panel: Considerations for an Oncology Company’s Autoimmune Side Hustle
Date and time: 9 November 2023, 11:40am ET / 16:40pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Jefferies London Healthcare Conference  
Fireside Chat
Date and time: 16 November 2023, 4:00am ET / 9:00am GMT
Location: London, UK
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Piper Sandler 35th Annual Healthcare Conference
Fireside Chat
Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com

Lauren Williams
Investase
+44 23 9438 7760
lauren@investase.com 


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.